Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM010
- Development stage
- Preclinical
- Lead developer
- Leadermed Group
01
Overview
LM010 is a preclinical-stage drug candidate being developed by LeaderMed Group in collaboration with Combiphar. The primary indication for LM010 is myocardial fibrosis, a pathological condition involving the scarring of heart tissue that often leads to impaired cardiac function and heart failure. As of early 2024, the program remains in the preclinical phase, and the developers have not yet disclosed the specific molecular target or the modality (such as small molecule or monoclonal antibody) of the compound. The development of LM010 is part of LeaderMed's broader strategy to address cardiovascular and metabolic diseases in the Asia-Pacific region.
- Other names
- LM-010LM010LM 010
Beyond the preview
Go deeper on LM010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM010.